Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases
Source: SeekingAlpha
2025-11-10 07:39:25 ET
More on Eli Lilly, MeiraGTx
- Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share
- Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
- Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
- Eli Lilly inks a licensing deal worth up to $1.2B for RNAi therapeutics
- Eli Lilly, Novo down after U.S. drug pricing deal
Read the full article on Seeking Alpha
For further details see:
Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases
MeiraGTx Holdings plc
NASDAQ: MGTX
MGTX Trading
5.81% G/L:
$7.28 Last:
187,632 Volume:
$6.95 Open:
MGTX Latest News
February 17, 2026 09:05:00 am
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
February 03, 2026 08:00:00 am
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
November 20, 2025 03:00:00 pm
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
MGTX Stock Data
$607,706,212
74,454,072
4.21%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
